ly3451838
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2018 (NCT03692949)
Timeline
Indications
Mechanism of action
ADCYAP1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ly3451838
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04498910 | Phase 2 | Nov 16, 2020 | Eli Lilly |
| NCT03692949 | Phase 1 | Dec 31, 2018 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1